Completed Heart, Stroke & Blood Lungs & Breathing

Long-term home monitoring of Heart Failure patients for improved care and reduced hospitalisation

In plain English

AI plain-English summary

A tiny pressure sensor, permanently implanted in a lung artery, could let heart failure patients be monitored from home and keep them out of hospital. Heart failure and pulmonary hypertension cause breathlessness and severely limit walking. Patients rely on a precise balance of three drug types: too little medication and they worsen; too much causes side effects or waste. The key metric for adjusting drugs is pulmonary artery pressure (PAP), but measuring it currently requires a hospital catheterisation procedure, which carries risk and inconvenience. Professor Chris McLeod at Imperial College London proposes implanting a miniature pressure sensor inside the artery. Patients or carers can then take a reading at any time using a pocket-sized radio reader, which automatically sends the data to the hospital. Professor Tarassenko’s group brings experience in real-time hospital monitoring and mobile-phone telehealth for chronic disease. If successful, this system would allow clinicians to fine-tune medication remotely, based on readings taken during normal daily activity—more accurate than a single measurement taken lying in a hospital bed. The result could be slower disease progression, fewer hospital readmissions, and 24/7 reassurance for patients. The research is applied and patient-focused, with no fundamental science component.

View original technical description
Many older people suffer from the long-term disabling illnesses of heart failure and/or pulmonary hypertension. The symptoms are shortage of breath and severely restricted walking range. Without medication, patients get progressively worse until the disease kills them. With medication – a combination of three types - the symptoms can be successfully alleviated. Both over-medication and under-medication can be medically dangerous and costly, either a waste of drugs, side effects or the patient requiring re-hospitalisation. The vital measurement for controlling medication is pulmonary artery pressure (pap) which currently can only be measured by catheterisation, involving a hospital procedure and risk. Professor Chris McLeod (Imperial College London) and colleagues propose to measure pap using a tiny pressure sensor placed securely within the artery. Measurements can then be made at any time by interrogating the sensor by radio from a pocket-sized reader. The reader will be permanently, wirelessly linked to the hospital. Professor Tarasssenko's research group has extensive technical and clinical experience of real-time monitoring of patients in hospital and of the use of mobile-phone based telehealth to improve the management of chronic disease. Close control of the medication is therefore possible, leading to improved patient condition, slower progression of the disease and reduced re-hospitalisation. Measurement quality is guaranteed and measurements during normal activity are better than current catheter-based measurements in a clinic or hospital bed. The patient will know that they have 24/7 care.

View the original record at the funder ↗

Related Research

Grants with similar aims, by meaning.

Totally automated blood pressure monitoring at home to improve care of patients with Heart Failure or Pulmonary Hypertension.
Comprehensive remote monitoring system for Congestive Heart Failure
Automatic identification of cardiorespiratory biomarkers for remote management of chronic conditions
Addition of Continuous Cardiac Output measurements to improve care of chronic cardiac patients at home
Continuous respiration monitoring using a novel, wearable capaciflector sensor for early detection of distress, enabling quicker intervention for improved patient outcomes.

Original classification

Research

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.